Future preclinical studies should analyse whether the administration of EVs loaded with overexpressed miR424 and MBL2 could enhance the protection and repair mechanism after IS and MI, thereby discovering new targets aimed at treating both ischaemic events. The gene discussed is MBL2; the disease is myocardial infarction.